Anti-inflammatory Dietary Intervention in Patients With Type 2 Diabetes: A Randomized Controlled Trial

NCT07656805 · tracked via the Priya Life Science China tracker

Sponsor

Anhui Medical University

Phase

Not applicable

Started

2026-06-03

Last updated

2026-06-18

Condition(s) studied

T2DM (Type 2 Diabetes Mellitus)

Investigational drug(s) / intervention(s)

Anti-inflammatory Dietary InterventionStandard Diabetes Dietary Advice

Anti-inflammatory Dietary Intervention: Participants in this group will receive a 4-week evidence-based anti-inflammatory dietary intervention in addition to routine diabetes care.

Standard Diabetes Dietary Advice: Participants will receive routine dietary guidance for diabetes management according to standard clinical dietary recommendations for 4 weeks.

Study summary

The goal of this clinical trial is to evaluate whether an evidence-based anti-inflammatory dietary intervention can reduce inflammation and improve glycemic control in patients with type 2 diabetes mellitus (T2DM). T2DM is a chronic metabolic disease characterized by elevated blood glucose levels and is closely associated with chronic low-grade inflammation.

The main questions it aims to answer are:

Does an anti-inflammatory dietary intervention reduce levels of hs-CRP, a key marker of chronic inflammation, in patients with T2DM? Does the intervention improve dietary inflammatory index (DII) scores and glycemic outcomes, including fasting blood glucose and 2-hour postprandial blood glucose? Researchers will compare an anti-inflammatory diet intervention group to a standard diabetes dietary control group to determine whether the anti-inflammatory dietary pattern provides additional benefits beyond routine dietary management.

Participants will:

Be randomly assigned to either the anti-inflammatory diet group or the standard diabetes diet group Receive dietary guidance based on structured anti-inflammatory food recommendations or routine diabetes dietary advice Complete dietary assessments, including 24-hour dietary recalls to calculate dietary inflammatory index (DII) Provide blood samples to measure hs-CRP, fasting blood glucose, and 2-hour postprandial blood glucose at baseline and after 4 weeks Complete questionnaires on dietary adherence and quality of life Participate in a 4-week intervention period with follow-up assessments

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Patients who meet the diagnostic criteria for type 2 diabetes mellitus (T2DM) according to the Guidelines for the Prevention and Treatment of Type 2 Diabetes Mellitus in China (2020 Edition); 2. Aged 18 years or older; 3. Able and willing to complete all study questionnaires; 4. Willing to provide blood samples for laboratory testing; 5. Possessing adequate communication and comprehension abilities, with no impairment of consciousness, and able to respond to investigators' questions; 6. Willing to participate in regular follow-up visits and assessments according to the study protocol and able to provide written informed consent. Exclusion Criteria: 1. Patients with a history of diseases affecting blood glucose metabolism, such as hyperthyroidism or Cushing's syndrome; 2. Pregnant or breastfeeding women; 3. Patients with severe hepatic dysfunction, renal dysfunction, heart failure, or malignant tumors; 4. Patients with acute or chronic infectious diseases accompanied by obvious signs of infection, including clinically diagnosed intestinal infections, respiratory tract infections, periodontitis, and other infectious conditions; 5. A history of recent use of medications that may affect inflammatory or metabolic status, such as nonsteroidal anti-inflammatory drugs (NSAIDs, e.g., aspirin) or glucocorticoids; 6. Patients who have undergone gastrointestinal surgery or have diseases that may affect the effectiveness of dietary intervention, such as malabsorption syndrome.

Primary outcome measure(s)

high-sensitivity C-reactive protein (hs-CRP) — Week 4

Trial sites (1)

Facility	City	Region	Status
The First Affiliated Hospital of Anhui Medical University	Hefei	Anhui	Recruiting

More Anhui Medical University trials in China

The Ma'Anshan Birth Cohort (MABC) Active, not recruiting

Personalized iTBS in Real-World Clinical Settings for Schizophrenia Recruiting

Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Artery Stenosis Patients: A Cohort Study Recruiting

Respiratory-gated Transcutaneous Auricular Vagus Nerve Stimulation for Improving Apathy in Parkinson's Disease Recruiting

Neuroimage-guided Dual-target Continuous Theta Burst Stimulation for Generalized Anxiety Disorder Active, not recruiting

Other trials for the same condition

Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients Recruiting

Chiglitazar Added to SGLT-2 Inhibitors for Type 2 Diabetes Recruiting

Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control Recruiting

A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin Starting soon

Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07656805 on ClinicalTrials.gov ↗ ← All trials in China